Active ShortageTier 3 — Critical

IFEX

BAXTER CORPORATION

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of IFEX in Canada?

Yes. IFEX 1G has an active shortage reported to Health Canada (last updated April 17, 2026).

Why is IFEX not available?

The reason the manufacturer reported: Shortage of an active ingredient.

When will IFEX be available again?

The manufacturer's estimated resolution date is September 30, 2026. This is an estimate and can change; follow this page to get an email when the status changes.

Can I still get this?Possibly — same-ingredient product records found

StatusActive Shortage

Same-ingredient products on file4 products

Expected resolution~2 days remaining (estimate)

Affected strength1G

Last updated2026-04-17

Other Products Containing the Same Active Ingredient

These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.

Closest Matches

IFEX PWS 1GM/VIAL

BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB

1G · DIN 00797227

Same strengthSame dosage formSame routeNo current shortage

Compare these two →

IFOSFAMIDE FOR INJECTION

FRESENIUS KABI CANADA LTD

1G · DIN 02246565

Same strengthSame dosage formSame routeNo current shortage

Compare these two →

Other Products

IFEX PWS 2G/VIAL

BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB

2G · DIN 00797235

Different strengthSame dosage formSame routeNo current shortage

Compare these two →

IFEX PWS 3GM/VIAL

BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB

3G · DIN 00808601

Different strengthSame dosage formSame routeNo current shortage

Compare these two →

What this means

Does this mean my pharmacy is out of stock?

Not necessarily — a national shortage doesn't mean every pharmacy has run out. Some locations may still have stock, especially of a specific strength or pack size.

What should I do?

Contact your pharmacy before your current supply runs low, and ask your pharmacist about next steps if they're out.

DIN

02241357

Strength

Dosage Form

POWDER FOR SOLUTION

Route

INTRAVENOUS

Active Ingredient

IFOSFAMIDE

See all IFOSFAMIDE products →

Compare with another product →

Product Monograph

Official Product Monograph (Health Canada)

View official Health Canada drug record ↗

Shortage Timeline

Approximate — based on the dates HPSC reports were last updated, not confirmed onset or resolution dates. Gaps between bars are periods with no shortage on file.

Active/anticipated Resolved

Shortage History

2026-04-17

Active Shortage

Shortage of an active ingredient.

Other Products from BAXTER CORPORATION

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

(20 MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP

DIN 00438014

(20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP

DIN 00786292

(20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP

DIN 00438049

(20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP

DIN 00786209

(20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP

DIN 00437999

(40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP

DIN 00786217